# data[].attributes.body
Daniel Dimitri has driven operations at PharmaForce in the role of chief executive officer since establishing the pharmacy services provider in 2016. He works directly alongside the board of directors, while also managing communications with major stakeholders and functioning as the public face of the company. As chief executive officer of PharmaForce, Daniel Dimitri is tasked with the development and execution of long-term strategic vision.

In addition to his work as an executive leader at PharmaForce, Daniel Dimitri is an active entrepreneur in Silicon Valley. He is well-versed in the challenges faced by startups in California’s technology sector, and excels as a risk mitigation professional. In the past, he worked as a manager of large-scale programs at Kaiser Permanente.

Mr. Dimitri studied business at the University of Maryland, graduating with a bachelor of science. When he is not overseeing account management and cloud-based technologies at PharmaForce, he enjoys leading an active lifestyle. His interests include snowboarding, surfing, and mixed martial arts.

# data[].attributes.attachment_link.readable_text
Surfing is a popular water sport in many coastal regions of the United States. It is a growing sport, with American youth comprising nearly one-third of the 3.5 million participants. The average surfer is 34 years old. America left its mark on the international stage in surfing at the 2020 Tokyo Olympics, with Carissa Moore winning the gold medal in the women's shortboard event. There are many physical and psychological benefits associated with surfing, but those new to surfing should be aware of several potential dangers.

Drowning is a serious concern for surfers, as it is for all athletes participating in water sports. Many different situations can result in a potential accidental drowning, ranging from falling unconscious after a collision to getting separated from the board while too far from land to swim back. Surfers, especially inexperienced individuals, should never go surfing alone. It is also important to take lessons and learn from more knowledgeable athletes, which can help prevent common accidents and mistakes.

Surfers must respect the ocean, which can present several risks, including riptides and the very waves surfers are riding. Riptides, also known as rips, are strong offshore currents created by inlets and estuaries. A riptide can move a surfer out to sea at speeds of up to eight feet per second, faster than an Olympic swimmer. Individuals must research local riptides and learn how to spot them from the beach and while on the ocean. Individuals caught in a rip should call loudly for help and swim parallel to the shore - attempting to swim directly to shore against the rip will result in fatigue, putting the surfer at risk.

When it comes to waves, surfers must understand their limitations. This is especially true for new surfers, who may be enticed by large waves but fail to appreciate their power. Some waves break with enough force to break bones, and a typical wipeout can result in various injuries.

Similarly, individuals must demonstrate proper care and respect for their surfboard and other boards on the water. Surfboards travel very quickly over waves and have a sharp point at the front, plus multiple blade-like fins underneath. Individuals must always be aware of other surfers in the area, and must do everything they can to keep their board under control. This includes monitoring the board's leash so that it does not get tangled with another surfer's arm or leg.

In addition to other boards, surfers must be aware of other people in the water, including locals. Regulars can sometimes be hostile to newcomers and tourists, and this hostility can manifest as aggression on the open water. Newcomers should practice good surf etiquette at all times. If locals are unusually aggressive, it may be better to find a new location. Surfers should also monitor for other people and activities happening in the area, such as jet skiers or speedboats towing people in tubes.

Finally, several types of marine life can pose a threat to surfers. It is important to learn about local marine life and ask about potential dangers at individual beaches. Sharks can be a concern in some places, though research has proven that sharks have no more interest in surfers than they do any other humans in the water, which is generally no interest at all. Still, one study found that 52 percent of surfers have seen a shark while surfing, so individuals should familiarize themselves with any species in their region. Additional marine life to learn about and avoid while surfing include urchins, jellyfish, stingrays, snakes, and seals.

# data[].attributes.attachment_link.description
Surfing is a popular water sport in many coastal regions of the United States. It is a growing sport, with American youth comprising nearly one-third of the 3.5 million participants. The average...

# data[].attributes.attachment_link.readable_text
​For more than three decades, the 340B Drug Pricing Program has helped qualified entities maximize what few federal resources are available. Stretching these resources allows pharmacy service providers to support more patients and offer a greater depth of services. Any drug manufacturer engaged in the Medicaid system is obligated to provide outpatient drugs covered under the 340B program at significantly reduced costs.

Many different facilities can qualify for the 340B Drug Pricing Program. Health centers, state-funded AIDS drug assistance programs, children's hospitals, and both Medicare and Medicaid disproportionate share hospitals can benefit from reduced 340B drug prices. The program emphasizes the needs of healthcare providers serving a large number of uninsured and low-income patients. Interested organizations must register and enroll with the 340B program through the Health Resources and Services Administration (HRSA). Eligible entities who adhere to all program regulations receive a 340B identification number that can be used with qualified vendors.

The 340B program is particularly beneficial to healthcare providers serving vulnerable communities that are disproportionately impacted by the rising costs of prescription drugs. More than 4,200 individual drug products increased in price from January 2022 to January 2023, with nearly half of these products increasing at a rate greater than the overall rate of inflation. Drugs increased by an average of 15.2 percent, for an average cost of nearly $600 per product.

Care facilities are expected to treat a disproportionate number of low-income Medicare and Medicaid patients. However, a March 2022 law granted select hospitals a temporary exemption from these requirements, as the COVID-19 public health emergency impacted their patient profiles. These exceptions ran through 2023. HRSA granted 53 of 61 exemption requests, according to the Government Accountability Office. In some cases, a facility's disproportionate share of uninsured patients was 9 percent off from 340B requirements, a testament to the widespread impact of the pandemic.

Facilities that save on 340B drugs direct those savings back to patients. Common examples include hospitals using 340B savings to pay for free vaccine initiatives and to provide health programs to the community. Hospitals can also care for more uninsured patients after entering the 340B program.

In 2023, more than 2,600 American hospitals were part of the 340B program. These hospitals benefit from pharmaceutical purchase savings ranging from 25 to 50 percent. Despite the considerable oversight and record of success, several parties have called for a reduction of 340B programming, or eliminating the program completely. These include efforts to greatly expand reporting requirements for qualified hospitals, making it more difficult and expensive to qualify for the program.

The 340B Drug Pricing Program has many supporters, including the American Hospital Association (AHA). The AHA has advised that all healthcare industry professionals do what they can to protect the program for all providers and to advocate for the Department of Health and Human Services to reverse all unlawful Medicare payment cuts. Related efforts include disrupting the drug manufacturing industry's attempts to illegally modify the 340B program and eliminating the orphan drug exclusion, which exempts certain pharmaceuticals from the program if they demonstrate low potential for profitability.

More information about the importance of the 340B Drug Pricing Program and how to advocate for the program can be found at aha.org.

# data[].attributes.attachment_link.title
The Importance of the 340B Drug Pricing Program

# data[].attributes.attachment_link.description
​For more than three decades, the 340B Drug Pricing Program has helped qualified entities maximize what few federal resources are available. Stretching these resources allows pharmacy service...